Gschwend J, Maier S, Flohr P, de Petriconi R, Hautmann R E
Urologische Universitätsklinik Ulm.
Urologe A. 1994 Sep;33(5):440-6.
Renal cell carcinoma invades the vena cava in 4-10% of cases. Another 10% of patients present with invasion of the renal vein. The surgical approach, complications and long-term outcome of 95 patients were investigated. Intraoperative complications occurred in 1 of 73 patients with involvement of the renal vein and 5 of 22 patients with vena cava thrombus. One patient in each group died due to pulmonary emboli in the perioperative period. Minor renal insufficiency occurred in 39 (54.2%) and 11 (50%) of the patients respectively. The rates of minor complications such as wound infections, haematoma and pneumonia were similar in the two groups. The mean intra-operative blood loss of 780 ml in patients undergoing tumour nephrectomy was significantly lower than the blood loss of 1485 ml in patients with tumour thrombus extension into the vena cava. The 5-year survival rate of patients with V1 tumours (71%) is comparable to that of patients without venous involvement. Tumour extension into the vena cava (V2) influences the 5-year survival rate significantly, decreasing it to 56.7%. In conclusion, long-term survival can be achieved for patients with renal cell carcinoma and venous involvement, though for patients with lymph node metastases or distant metastases only short-term palliation can be achieved. However, the potential benefits should be carefully weighed against the possible complications, the surgical morbidity and the resources expended in vena cava resection.
肾细胞癌在4%-10%的病例中侵犯腔静脉。另有10%的患者表现为肾静脉受侵。对95例患者的手术方法、并发症及长期预后进行了研究。73例肾静脉受累患者中有1例发生术中并发症,22例腔静脉血栓患者中有5例发生术中并发症。每组各有1例患者在围手术期因肺栓塞死亡。两组患者分别有39例(54.2%)和11例(50%)出现轻度肾功能不全。两组伤口感染、血肿和肺炎等轻微并发症的发生率相似。接受肿瘤肾切除术患者的术中平均失血量为780 ml,显著低于肿瘤血栓延伸至腔静脉患者的1485 ml失血量。V1期肿瘤患者的5年生存率(71%)与无静脉受累患者相当。肿瘤延伸至腔静脉(V2期)显著影响5年生存率,降至56.7%。总之,肾细胞癌合并静脉受累患者可实现长期生存,不过对于有淋巴结转移或远处转移的患者只能实现短期姑息治疗。然而,应仔细权衡潜在益处与可能的并发症、手术发病率以及腔静脉切除所消耗的资源。